Aumolertinib challenge as an optional treatment in advanced non small-cell lung cancer after osimertinib failure with epidermal growth factor receptor-sensitive mutation: A case series

Osimertinib, as the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been recommended universally as the priority front-line therapeutic for advanced non-small cell lung cancer (NSCLC) carrying EGFR-sensitive mutations. However, patients inevitably...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xinjing, Ding, Jianghua, Leng, Zhaohui, Song, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533661/
https://www.ncbi.nlm.nih.gov/pubmed/36276494
http://dx.doi.org/10.3892/ol.2022.13520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533661/
https://www.ncbi.nlm.nih.gov/pubmed/36276494
http://dx.doi.org/10.3892/ol.2022.13520

Ejemplares similares